Navigation Links
Accera Announces Initiation of Clinical Trial for AC-1204
Date:11/26/2012

imately 60 clinical sites in the US and is expected to enroll more than 400 patients.  This study will evaluate the effects of once daily dosing of AC-1204 for 26 weeks on cognition, pharmacokinetic measures, activities of daily living, resource utilization, and quality of life among subjects with mild-to-moderate AD. 

The primary endpoint will examine the effects of AC-1204 on memory and cognition as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) after 26 weeks among both carriers and non carriers of the epsilon 4 variant of the gene apolipoprotein E (APOE4).  Previous studies demonstrated proof of concept for the company's unique approach. 

About Accera 
Accera, Inc. is a privately held commercial-stage healthcare company that developed and now markets Axona in the US.  Accera is engaged in the research, development and commercialization of other clinical applications for Axona and AC-1204 in acute and chronic neurodegenerative diseases.  For more information about Accera, please visit www.accerapharma.comAccera, Inc.

Tiberend Strategic Advisors, Inc.(303) 999-3705

(212) 827-0020Bill Poncy

Andrew MielachVP Commercial Development

amielach@tiberend.com bponcy@accerapharma.com
'/>"/>

SOURCE Accera, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... BRANFORD, Connecticut, June 15, 2011 , ... has killed dozens and,hospitalized thousands across Europe has been ... to generate the,"most accurate and detailed genetic analysis to ... ] ,The sequencing was performed by scientists at the ...
... Systems, Inc. (NYSE: VAR ), the world,s ... radiotherapy, announced today it has received Shonin approval from ... to market the TrueBeam™ system for image-guided radiotherapy and ... breast, prostate, head and neck, and other types of ...
Cached Medicine Technology:Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 2Deadly E. Coli Strain Sequenced With Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date 3TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval 2TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval 3
(Date:12/25/2014)... Dec. 25, 2014 (HealthDay News) -- The risk of ... holidays, so you need to be extra cautious, an ... we see a significant increase in patients coming in ... the Suffolk County Volunteer Firefighters Burn Center of Stony ... should be full of joy, but if not careful, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... a "fountain of youth" drug that can delay the effects ... new study suggests. Seniors received a significant boost to ... genetic signaling pathway linked to aging and immune function, researchers ... experimental medication, a version of the drug rapamycin, improved the ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part ... mobile applications on the iOS, Android, and Windows markets. Andrew ... the app review and shared with viewers how this is ... old saying goes, “A picture says a thousand words.” It’s ... a single image, because each picture holds a unique and ...
(Date:12/25/2014)... Each year trauma accounts for approximately ... admissions across the nation (according to the Centers ... National Hospital Ambulatory Medical Care Survey collected data ... 2010. They estimated that there were between 3.5 and ... primary diagnosis of broken bone or fracture. , ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Over 700 ... to their local communities. That is 700 smiling little ... single gift. Additionally over $6000 in monetary donations was ... offset some of the expenses they incur through the ... drive were A Child's Haven , Shrine's Children's ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife Donates Over 700 Toys This Year 2
... News) -- Exposure to secondhand smoke could affect hearing ... loss during adolescence, a new study indicates. These ... exposed to secondhand smoke, the researchers warned. Roughly ... exposed to secondhand smoke, reported the study,s authors. These ...
... HealthDay Reporter , MONDAY, July 18 (HealthDay ... blood pressure modestly among hypertensive patients, a small, new ... refined carbohydrates -- such as white bread and white ... protein "might be an important component of nutrition intervention ...
... JULY 18, 2011 Registration is now open for ... the Cardiovascular Research Foundation, which will return to San ... year, groundbreaking scientific advances in interventional cardiology presented at ... cause of death in the United States, is viewed ...
... journal Science Signaling Van Andel Research Institute ... anti-malaria drug chloroquine represses inflammation, which may provide a ... multitude of autoimmune diseases such as arthritis, multiple sclerosis, ... anti-malaria drug that inhibits the growth of parasites. For ...
... Researchers at Mount Sinai School of Medicine have identified how ... diabetes, also possibly kills nerve cells in the brain, thereby ... the generation of amyloid-beta (Abeta) in the brain. Abeta plays ... researchers previously linked SorCS1 to Alzheimer,s disease and identified where ...
... pace of translating science into real-life solutions for patients ... Health to expand its work over the next five ... (CTSI) is among 10 institutes nationwide to receive the ... first five years of the NIH,s Clinical and Translational ...
Cached Medicine News:Health News:Secondhand Smoke Linked to Hearing Loss in Teens 2Health News:Small Study Suggests Milk, Soy Proteins Lower Blood Pressure Modestly 2Health News:Small Study Suggests Milk, Soy Proteins Lower Blood Pressure Modestly 3Health News:Innovations in cardiovascular therapies and treatments will be presented at TCT 2011 2Health News:Chloroquine finding may lead to treatments for arthritis, cancer and other diseases 2Health News:Chloroquine finding may lead to treatments for arthritis, cancer and other diseases 3Health News:Researchers identify how a gene linked to both Alzheimer's disease and type 2 diabetes works 2Health News:UCSF receives $112 million to help translate science into cures 2Health News:UCSF receives $112 million to help translate science into cures 3Health News:UCSF receives $112 million to help translate science into cures 4
... to its design, this is the ... stone therapy in urinary and biliary ... a multipurpose lithotripter with other applications ... nephrolithotomy. ,The basic system comprises the ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... Compact Sigma is designed to easily ... precise mechanical coupling eliminates clumsy time ... performed as well. Dorniers patented isocentric ... ,Positioning is simple using the Dornier ...
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
Medicine Products: